Search

Your search keyword '"Duly-Bouhanick, B."' showing total 33 results
Start Over Author "Duly-Bouhanick, B."
33 results on '"Duly-Bouhanick, B."'

1. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney

Author

Halimi, J, Sarafidis, P, Azizi, M, Bilo, G, Burkard, T, Bursztyn, M, Camafort, M, Chapman, N, Cottone, S, de Backer, T, Deinum, J, Delmotte, P, Dorobantu, M, Doumas, M, Dusing, R, Duly-Bouhanick, B, Fauvel, J, Fesler, P, Gaciong, Z, Gkaliagkousi, E, Gordin, D, Grassi, G, Grassos, C, Guerrot, D, Huart, J, Izzo, R, Jaén Águila, F, Járai, Z, Kahan, T, Kantola, I, Kociánová, E, Limbourg, F, Lopez-Sublet, M, Mallamaci, F, Manolis, A, Marketou, M, Mayer, G, Mazza, A, Macintyre, I, Mourad, J, Muiesan, M, Nasr, E, Nilsson, P, Oliveras, A, Ormezzano, O, Paixão-Dias, V, Papadakis, I, Papadopoulos, D, Perl, S, Polónia, J, Pontremoli, R, Pucci, G, Robles, N, Rubin, S, Ruilope, L, Rump, L, Saeed, S, Sanidas, E, Sarzani, R, Schmieder, R, Silhol, F, Sokolovic, S, Solbu, M, Soucek, M, Stergiou, G, Sudano, I, Tabbalat, R, Tengiz, I, Triantafyllidi, H, Tsioufis, K, Václavík, J, van der Giet, M, der Niepen, P, Veglio, F, Venzin, R, Viigimaa, M, Weber, T, Widimsky, J, Wuerzner, G, Zelveian, P, Zebekakis, P, Lueders, S, Persu, A, Kreutz, R, Vogt, L, Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Jaén Águila F, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg F, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre I, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, der Niepen PV, Veglio F, Venzin R, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, Vogt L., Halimi, J, Sarafidis, P, Azizi, M, Bilo, G, Burkard, T, Bursztyn, M, Camafort, M, Chapman, N, Cottone, S, de Backer, T, Deinum, J, Delmotte, P, Dorobantu, M, Doumas, M, Dusing, R, Duly-Bouhanick, B, Fauvel, J, Fesler, P, Gaciong, Z, Gkaliagkousi, E, Gordin, D, Grassi, G, Grassos, C, Guerrot, D, Huart, J, Izzo, R, Jaén Águila, F, Járai, Z, Kahan, T, Kantola, I, Kociánová, E, Limbourg, F, Lopez-Sublet, M, Mallamaci, F, Manolis, A, Marketou, M, Mayer, G, Mazza, A, Macintyre, I, Mourad, J, Muiesan, M, Nasr, E, Nilsson, P, Oliveras, A, Ormezzano, O, Paixão-Dias, V, Papadakis, I, Papadopoulos, D, Perl, S, Polónia, J, Pontremoli, R, Pucci, G, Robles, N, Rubin, S, Ruilope, L, Rump, L, Saeed, S, Sanidas, E, Sarzani, R, Schmieder, R, Silhol, F, Sokolovic, S, Solbu, M, Soucek, M, Stergiou, G, Sudano, I, Tabbalat, R, Tengiz, I, Triantafyllidi, H, Tsioufis, K, Václavík, J, van der Giet, M, der Niepen, P, Veglio, F, Venzin, R, Viigimaa, M, Weber, T, Widimsky, J, Wuerzner, G, Zelveian, P, Zebekakis, P, Lueders, S, Persu, A, Kreutz, R, Vogt, L, Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Jaén Águila F, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg F, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre I, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, der Niepen PV, Veglio F, Venzin R, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, and Vogt L.

Abstract

Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70–95%]) than MRA (20% [10–30%]), SGLT2i (30% [20–50%]) or (GLP1-RA (10% [5–15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15–40%) vs 18% [10%–25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5–5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers’ dosage reduction was the usual management.

Published
2024

2. Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire

Author

Halimi, J, Sarafidis, P, Azizi, M, Bilo, G, Burkard, T, Bursztyn, M, Camafort, M, Chapman, N, Cottone, S, de Backer, T, Deinum, J, Delmotte, P, Dorobantu, M, Doumas, M, Dusing, R, Duly-Bouhanick, B, Fauvel, J, Fesler, P, Gaciong, Z, Gkaliagkousi, E, Gordin, D, Grassi, G, Grassos, C, Guerrot, D, Huart, J, Izzo, R, Águila, F, Járai, Z, Kahan, T, Kantola, I, Kociánová, E, Limbourg, F, Lopez-Sublet, M, Mallamaci, F, Manolis, A, Marketou, M, Mayer, G, Mazza, A, Macintyre, I, Mourad, J, Muiesan, M, Nasr, E, Nilsson, P, Oliveras, A, Ormezzano, O, Paixão-Dias, V, Papadakis, I, Papadopoulos, D, Perl, S, Polónia, J, Pontremoli, R, Pucci, G, Robles, N, Rubin, S, Ruilope, L, Rump, L, Saeed, S, Sanidas, E, Sarzani, R, Schmieder, R, Silhol, F, Sokolovic, S, Solbu, M, Soucek, M, Stergiou, G, Sudano, I, Tabbalat, R, Tengiz, I, Triantafyllidi, H, Tsioufis, K, Václavík, J, van der Giet, M, Van der Niepen, P, Veglio, F, Venzin, R, Viigimaa, M, Weber, T, Widimsky, J, Wuerzner, G, Zelveian, P, Zebekakis, P, Lueders, S, Persu, A, Kreutz, R, Vogt, L, Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Águila FJ, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg FP, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre IM, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, Van der Niepen P, Veglio F, Venzin RM, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, Vogt L, Halimi, J, Sarafidis, P, Azizi, M, Bilo, G, Burkard, T, Bursztyn, M, Camafort, M, Chapman, N, Cottone, S, de Backer, T, Deinum, J, Delmotte, P, Dorobantu, M, Doumas, M, Dusing, R, Duly-Bouhanick, B, Fauvel, J, Fesler, P, Gaciong, Z, Gkaliagkousi, E, Gordin, D, Grassi, G, Grassos, C, Guerrot, D, Huart, J, Izzo, R, Águila, F, Járai, Z, Kahan, T, Kantola, I, Kociánová, E, Limbourg, F, Lopez-Sublet, M, Mallamaci, F, Manolis, A, Marketou, M, Mayer, G, Mazza, A, Macintyre, I, Mourad, J, Muiesan, M, Nasr, E, Nilsson, P, Oliveras, A, Ormezzano, O, Paixão-Dias, V, Papadakis, I, Papadopoulos, D, Perl, S, Polónia, J, Pontremoli, R, Pucci, G, Robles, N, Rubin, S, Ruilope, L, Rump, L, Saeed, S, Sanidas, E, Sarzani, R, Schmieder, R, Silhol, F, Sokolovic, S, Solbu, M, Soucek, M, Stergiou, G, Sudano, I, Tabbalat, R, Tengiz, I, Triantafyllidi, H, Tsioufis, K, Václavík, J, van der Giet, M, Van der Niepen, P, Veglio, F, Venzin, R, Viigimaa, M, Weber, T, Widimsky, J, Wuerzner, G, Zelveian, P, Zebekakis, P, Lueders, S, Persu, A, Kreutz, R, Vogt, L, Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Águila FJ, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg FP, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre IM, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, Van der Niepen P, Veglio F, Venzin RM, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, and Vogt L

Abstract

Objective: Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear. Methods: A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management of CKD patients referred to ESH-Hypertension Excellence Centres (ESH-ECs) at first referral visit. The questionnaire contained 64 questions with which ESH-ECs representatives were asked to estimate preexisting CKD management quality. Results: Overall, 88 ESH-ECs from 27 countries participated (fully completed surveys: 66/88 [75.0%]). ESH-ECs reported that 28% (median, interquartile range: 15–50%) had preexisting CKD, with 10% of them (5–30%) previously referred to a nephrologist, while 30% (15–40%) had resistant hypertension. The reported rate of previous recent (<6months) estimated glomerular filtration rate (eGFR) and urine albumin–creatinine ratio (UACR) testing were 80% (50–95%) and 30% (15–50%), respectively. The reported use of renin-angiotensin system blockers was 80% (70–90%). When a nephrologist was part of the ESH-EC teams the reported rates SGLT2 inhibitors (27.5% [20 – 40%] vs. 15% [10 – 25], P 1⁄4 0.003), GLP1-RA (10% [10 – 20%] vs. 5% [5 – 10%], P 1⁄4 0.003) and mineralocorticoid receptor antagonists (20% [10 – 30%] vs. 15% [10 – 20%], P 1⁄4 0.05) use were greater as compared to ESH-ECs without nephrologist participation. The rate of reported resistant hypertension, recent eGFR and UACR results and management of CKD patients prior to referral varied widely across countries. Conclusions: Our estimation indicates deficits regarding CKD screening, use of nephroprotective drugs and referral to nephrologists before referral to ESH-ECs but results varied widely across countries. This information can be used to build specific programs to improve care in hypertensives with CKD.

Published
2024

4. Prognostic value of glycosuria amount durin hyperglycaemia in patients with type 1 diabetes and risk for diabetic nephropathy

Author

M, MARRE, C, CARPENTIER, Mohammedi, K., Belhatem, Narimène, Duly-Bouhanick, B., Rohmer, Vincent, Rodien, P, Bumbu, Anisoara, Hadjadj, S., R, ROUSSEL, L, POTIER, Velho, G., Dubois, Séverine, Service d'endocrinologie, diabétologie et nutrition [CHU Bichat], Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Stress Oxydant et Pathologies Métaboliques (SOPAM), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques ( IRTOMIT), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de Diabétologie, Hôtel-Dieu de Paris

Subjects
[SDV]Life Sciences [q-bio], [SDV.BC]Life Sciences [q-bio]/Cellular Biology, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2017

5. Abondance de la glycosuria pendant l’hyperglycémie et risqué de néphropathie à long terme dans le diabète de type 1

Author

C, CARPENTIER, Velho, G., Mohammedi, K., Belhatem, Narimène, Duly-Bouhanick, B., Rohmer, Vincent, Rodien, P., Hadjadj, S., R, ROUSSEL, L, POTIER, M, MARRE, Dubois, Séverine, Service de Diabétologie, Hôtel-Dieu de Paris, Service d'endocrinologie, diabétologie et nutrition [CHU Bichat], Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Stress Oxydant et Pathologies Métaboliques (SOPAM), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Endocrinologie (ANGERS - Endocrino), Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)

Subjects
[SDV]Life Sciences [q-bio], [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2017

6. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: Contributions of the GERODIAB study

Author

Bauduceau, B, Blicklé, J-F, Bourdel-Marchasson, I, Constans, T, Doucet, J, Fagot-Campagna, A, Kaloustian, E, Lassmann-Vague, V, Lecomte, P, Tessier, D, Verny, C, Vischer, U, Affres, H, Alix, M, Archambeaud, F, Barrou, Z, Beau, P, Beltran, S, Benoit, C, Beressi, J-P, Bernachon, F, Berne, C, Berrut, G, Blaimont, A, Blickle, J-F, Boda-Buccino, M, Bohatier, J, Böhme, P, Bordier, L, Bouchou, K, Bouillet, B, Bouilloud, F, Bouix, R, Boulanger, E, Bourgon, C, Bourrinet, E, Brocker, P, Bruckert, I, Capet, C, Carette, C, Cariou, B, Carreau, A, Vaurie, C Chaillou, Chamouni, S, Ciangura, C, Collet-Gaudillat, C, Combes-Moukhovsky, M-E, Cordonnier, M, Cuperlier, A, Dambre, D, D'Avigneau, J, De Botton, P, Degros, V, Delamarre-Damier, F, Denat, S, Desbiez, F, Deumier, B, Dorey, F, Dresco, E, Drutel, A, De Saint Germain, E Du Rosel, Dubois-Laforgue, D, Duly-Bouhanick, B, Dupuy, O, Dusselier, L, Faucher-Kareche, S, Fendri, S, Fontaine, P, Galinat, S, Gentric, A, Gin, H, Glaise, F, Godeau, T, Gonzales, B, Got, I, Guerci, B, Guillausseau, P-J, Hadjadj, S, Hadjali, Y, Halbron, M, Halimi, S, Halter, C, Hanaire, H, Hardy, V, Hartemann-Heurtier, A, Haulot, J-P, Hequet, F, Issa-Sayegh, M, Jan, P, Jeandidier, N, Joseph-Henri, H, Julier, I, Kerlan, V, Kharitonnoff, T, Ladsous, M, Lahaxe, L, Lamaraud, M-P, Lassenne, E, Lecerf, J-M, Leroux, I, Lesven, S, Levy, M, Lopez, S, Makiza, F, Manckoundia, P, Pomeau, C Marquis, Mayaudon, H, Micheli, S, Mira, R, Monnier, F, Mosnier-Pudar, H, Neri, N, Normand, I, Paccalin, M, Pagu, C, Paris, D, Penfornis, A, Perie, J-L, Petit, J-M, Petit-Aubert, G, Pichot-Duclos, B, Pivois, L, Popelier, M, Poulingue, G, Priner, M, Quipourt, V, Rasamisoa, M, Richard, J-L, Rigalleau, V, Roudat, N, Sanz, C, Serot, J-M, Sifi, D, Sirvain, S, Slimani, A, Sonnet, E, Sosset, C, Soualah, A, Stroea, A, Tauveron, I, Timsit, J, Tschudnowsky, M, Vambergue, A, Verier-Mine, O, Virally, M, Bordier, L., Buysschaert, M., Bauduceau, B., Doucet, J., Verny, C., Lassmann Vague, V., and Le Floch, J.P.

Published
2015
Full Text
View/download PDF

10. Comparaison de la stabilité hémodynamique peropératoire lors d’une surrénalectomie pour phéochromocytome entre une préparation anti-hypertensive préopératoire courte vs longue

Author

Gryn, A., primary, Duly-Bouhanick, B., additional, Bennet, A., additional, Almont, T., additional, Beauval, J., additional, Gas, J., additional, Roumiguié, M., additional, Thoulouzan, M., additional, Vezzosi, D., additional, Caron, P., additional, Amar, J., additional, Chamontin, B., additional, Gamé, X., additional, Malavaud, B., additional, Soulié, M., additional, Rischmann, P., additional, and Huyghe, E., additional

Published
2015
Full Text
View/download PDF

11. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: Contributions of the GERODIAB study

Author

Bordier, L., primary, Buysschaert, M., additional, Bauduceau, B., additional, Doucet, J., additional, Verny, C., additional, Lassmann Vague, V., additional, Le Floch, J.P., additional, Bauduceau, B, additional, Blicklé, J-F, additional, Bourdel-Marchasson, I, additional, Constans, T, additional, Doucet, J, additional, Fagot-Campagna, A, additional, Kaloustian, E, additional, Lassmann-Vague, V, additional, Lecomte, P, additional, Tessier, D, additional, Verny, C, additional, Vischer, U, additional, Affres, H, additional, Alix, M, additional, Archambeaud, F, additional, Barrou, Z, additional, Beau, P, additional, Beltran, S, additional, Benoit, C, additional, Beressi, J-P, additional, Bernachon, F, additional, Berne, C, additional, Berrut, G, additional, Blaimont, A, additional, Blickle, J-F, additional, Boda-Buccino, M, additional, Bohatier, J, additional, Böhme, P, additional, Bordier, L, additional, Bouchou, K, additional, Bouillet, B, additional, Bouilloud, F, additional, Bouix, R, additional, Boulanger, E, additional, Bourgon, C, additional, Bourrinet, E, additional, Brocker, P, additional, Bruckert, I, additional, Capet, C, additional, Carette, C, additional, Cariou, B, additional, Carreau, A, additional, Vaurie, C Chaillou, additional, Chamouni, S, additional, Ciangura, C, additional, Collet-Gaudillat, C, additional, Combes-Moukhovsky, M-E, additional, Cordonnier, M, additional, Cuperlier, A, additional, Dambre, D, additional, D'Avigneau, J, additional, De Botton, P, additional, Degros, V, additional, Delamarre-Damier, F, additional, Denat, S, additional, Desbiez, F, additional, Deumier, B, additional, Dorey, F, additional, Dresco, E, additional, Drutel, A, additional, De Saint Germain, E Du Rosel, additional, Dubois-Laforgue, D, additional, Duly-Bouhanick, B, additional, Dupuy, O, additional, Dusselier, L, additional, Faucher-Kareche, S, additional, Fendri, S, additional, Fontaine, P, additional, Galinat, S, additional, Gentric, A, additional, Gin, H, additional, Glaise, F, additional, Godeau, T, additional, Gonzales, B, additional, Got, I, additional, Guerci, B, additional, Guillausseau, P-J, additional, Hadjadj, S, additional, Hadjali, Y, additional, Halbron, M, additional, Halimi, S, additional, Halter, C, additional, Hanaire, H, additional, Hardy, V, additional, Hartemann-Heurtier, A, additional, Haulot, J-P, additional, Hequet, F, additional, Issa-Sayegh, M, additional, Jan, P, additional, Jeandidier, N, additional, Joseph-Henri, H, additional, Julier, I, additional, Kerlan, V, additional, Kharitonnoff, T, additional, Ladsous, M, additional, Lahaxe, L, additional, Lamaraud, M-P, additional, Lassenne, E, additional, Lecerf, J-M, additional, Leroux, I, additional, Lesven, S, additional, Levy, M, additional, Lopez, S, additional, Makiza, F, additional, Manckoundia, P, additional, Pomeau, C Marquis, additional, Mayaudon, H, additional, Micheli, S, additional, Mira, R, additional, Monnier, F, additional, Mosnier-Pudar, H, additional, Neri, N, additional, Normand, I, additional, Paccalin, M, additional, Pagu, C, additional, Paris, D, additional, Penfornis, A, additional, Perie, J-L, additional, Petit, J-M, additional, Petit-Aubert, G, additional, Pichot-Duclos, B, additional, Pivois, L, additional, Popelier, M, additional, Poulingue, G, additional, Priner, M, additional, Quipourt, V, additional, Rasamisoa, M, additional, Richard, J-L, additional, Rigalleau, V, additional, Roudat, N, additional, Sanz, C, additional, Serot, J-M, additional, Sifi, D, additional, Sirvain, S, additional, Slimani, A, additional, Sonnet, E, additional, Sosset, C, additional, Soualah, A, additional, Stroea, A, additional, Tauveron, I, additional, Timsit, J, additional, Tschudnowsky, M, additional, Vambergue, A, additional, Verier-Mine, O, additional, and Virally, M, additional

Published
2015
Full Text
View/download PDF

12. Pratique des endocrinologues français en lipidologie : évaluation lors des situations complexes à la frontière des recommandations

Author

Lecus, A., primary, Colin, C., additional, Touzet, S., additional, Denis, A., additional, Verges, B., additional, Charrière, S., additional, Valero, R., additional, Béliard, S., additional, Duly-Bouhanick, B., additional, Durlach, V., additional, Bonnet, F., additional, Bruckert, E., additional, Cariou, B., additional, Raverot, G., additional, Chabrier, G., additional, and Moulin, P., additional

Published
2015
Full Text
View/download PDF

14. Étude de l’amélioration du contrôle de la stabilité hémodynamique peropératoire de la surrénalectomie laparoscopique pour phéochromocytome

Author

Gryn, A., primary, Gas, J., additional, Thoulouzan, M., additional, Almont, T., additional, Beauval, J., additional, Roumiguié, M., additional, Crenn, G., additional, Bennet, A., additional, Vezzosi, D., additional, Caron, P., additional, Duly-bouhanick, B., additional, Amar, J., additional, Chamontin, B., additional, Atallah, F., additional, Mazerolles, M., additional, Rischmann, P., additional, Soulié, M., additional, and Huyghe, E., additional

Published
2014
Full Text
View/download PDF

15. Évaluation des complications majeures de la surrénalectomie laparoscopique : à propos de 469 cas

Author

Gryn, A., primary, Gas, J., additional, Thoulouzan, M., additional, Roumiguié, M., additional, Beauval, J., additional, Crenn, G., additional, Duly-Bouhanick, B., additional, Amar, J., additional, Chamontin, B., additional, Bennet, A., additional, Vezzosi, D., additional, Caron, P., additional, Game, X., additional, Malavaud, B., additional, Soulié, M., additional, Rischmann, P., additional, and Huyghe, E., additional

Published
2014
Full Text
View/download PDF

18. Concerns over the consequences of regional disparities for elderly French type 2 diabetes patients in the Gerodiab study

Author

Le Floch, J.-P., primary, Doucet, J., additional, Bauduceau, B., additional, Verny, C., additional, Bauduceau, B, additional, Blicklé, J-F, additional, Bourdel-Marchasson, I, additional, Constans, T, additional, Doucet, J, additional, Fagot-Campagna, A, additional, Kaloustian, E, additional, Lassmann-Vague, V, additional, Lecomte, P, additional, Tessier, D, additional, Verny, C, additional, Vischer, U, additional, Affres, H, additional, Alix, M, additional, Archambeaud, F, additional, Barrou, Z, additional, Beau, P, additional, Beltran, S, additional, Benoit, C, additional, Beressi, J-P, additional, Bernachon, F, additional, Berne, C, additional, Berrut, G, additional, Blaimont, A, additional, Blickle, J-F, additional, Boda-Buccino, M, additional, Bohatier, J, additional, Böhme, P, additional, Bordier, L, additional, Bouchou, K, additional, Bouillet, B, additional, Bouilloud, F, additional, Bouix, R, additional, Boulanger, E, additional, Bourgon, C, additional, Bourrinet, E, additional, Brocker, P, additional, Bruckert, I, additional, Capet, C, additional, Carette, C, additional, Cariou, B, additional, Carreau, A, additional, Vaurie, C Chaillou, additional, Chamouni, S, additional, Ciangura, C, additional, Collet-Gaudillat, C, additional, Combes-Moukhovsky, M-E, additional, Cordonnier, M, additional, Cuperlier, A, additional, Dambre, D, additional, D'Avigneau, J, additional, De Botton, P, additional, Degros, V, additional, Delamarre-Damier, F, additional, Denat, S, additional, Desbiez, F, additional, Deumier, B, additional, Dorey, F, additional, Dresco, E, additional, Drutel, A, additional, De Saint Germain, E Du Rosel, additional, Dubois-Laforgue, D, additional, Duly-Bouhanick, B, additional, Dupuy, O, additional, Dusselier, L, additional, Faucher-Kareche, S, additional, Fendri, S, additional, Fontaine, P, additional, Galinat, S, additional, Gentric, A, additional, Gin, H, additional, Glaise, F, additional, Godeau, T, additional, Gonzales, B, additional, Got, I, additional, Guerci, B, additional, Guillausseau, P-J, additional, Hadjadj, S, additional, Hadjali, Y, additional, Halbron, M, additional, Halimi, S, additional, Halter, C, additional, Hanaire, H, additional, Hardy, V, additional, Hartemann-Heurtier, A, additional, Haulot, J-P, additional, Hequet, F, additional, Issa-Sayegh, M, additional, Jan, P, additional, Jeandidier, N, additional, Joseph-Henri, H, additional, Julier, I, additional, Kerlan, V, additional, Kharitonnoff, T, additional, Ladsous, M, additional, Lahaxe, L, additional, Lamaraud, M-P, additional, Lassenne, E, additional, Lecerf, J-M, additional, Leroux, I, additional, Lesven, S, additional, Levy, M, additional, Lopez, S, additional, Makiza, F, additional, Manckoundia, P, additional, Pomeau, C Marquis, additional, Mayaudon, H, additional, Micheli, S, additional, Mira, R, additional, Monnier, F, additional, Mosnier-Pudar, H, additional, Neri, N, additional, Normand, I, additional, Paccalin, M, additional, Pagu, C, additional, Paris, D, additional, Penfornis, A, additional, Perie, J-L, additional, Petit, J-M, additional, Petit-Aubert, G, additional, Pichot-Duclos, B, additional, Pivois, L, additional, Popelier, M, additional, Poulingue, G, additional, Priner, M, additional, Quipourt, V, additional, Rasamisoa, M, additional, Richard, J-L, additional, Rigalleau, V, additional, Roudat, N, additional, Sanz, C, additional, Serot, J-M, additional, Sifi, D, additional, Sirvain, S, additional, Slimani, A, additional, Sonnet, E, additional, Sosset, C, additional, Soualah, A, additional, Stroea, A, additional, Tauveron, I, additional, Timsit, J, additional, Tschudnowsky, M, additional, Vambergue, A, additional, Verier-Mine, O, additional, and Virally, M, additional

Published
2014
Full Text
View/download PDF

21. Laparoscopie rétropéritonéale par abord rétrograde de la surrénale, à propos d’une série de 279 cas

Author

Huyghe, E., primary, Crenn, G., additional, Vezzosi, D., additional, Grunenwald, S., additional, Delaunay, B., additional, Salloum, A., additional, Thoulouzan, M., additional, Seguin, P., additional, Atallah, F., additional, Mazerolles, M., additional, Duly-Bouhanick, B., additional, Bennet, A., additional, Amar, J., additional, Rischmann, P., additional, Chamontin, B., additional, Caron, P., additional, and Soulie, M., additional

Published
2012
Full Text
View/download PDF

22. Résultats carcinologiques de la chirurgie surrénalienne pour métastase

Author

Huyghe, E., primary, Crenn, G., additional, Vezzosi, D., additional, Grunenwald, S., additional, Delaunay, B., additional, Salloum, A., additional, Thoulouzan, M., additional, Seguin, P., additional, Atallah, F., additional, Mazerolles, M., additional, Duly-Bouhanick, B., additional, Bennet, A., additional, Amar, J., additional, Rischmann, P., additional, Chamontin, B., additional, Caron, P., additional, and Soulie, M., additional

Published
2012
Full Text
View/download PDF

25. Concerns over the consequences of regional disparities for elderly French type 2 diabetes patients in the Gerodiab study

Author

Bauduceau, B, Blicklé, J-F, Bourdel-Marchasson, I, Constans, T, Doucet, J, Fagot-Campagna, A, Kaloustian, E, Lassmann-Vague, V, Lecomte, P, Tessier, D, Verny, C, Vischer, U, Affres, H, Alix, M, Archambeaud, F, Barrou, Z, Beau, P, Beltran, S, Benoit, C, Beressi, J-P, Bernachon, F, Berne, C, Berrut, G, Blaimont, A, Blickle, J-F, Boda-Buccino, M, Bohatier, J, Böhme, P, Bordier, L, Bouchou, K, Bouillet, B, Bouilloud, F, Bouix, R, Boulanger, E, Bourgon, C, Bourrinet, E, Brocker, P, Bruckert, I, Capet, C, Carette, C, Cariou, B, Carreau, A, Vaurie, C Chaillou, Chamouni, S, Ciangura, C, Collet-Gaudillat, C, Combes-Moukhovsky, M-E, Cordonnier, M, Cuperlier, A, Dambre, D, D'Avigneau, J, De Botton, P, Degros, V, Delamarre-Damier, F, Denat, S, Desbiez, F, Deumier, B, Dorey, F, Dresco, E, Drutel, A, De Saint Germain, E Du Rosel, Dubois-Laforgue, D, Duly-Bouhanick, B, Dupuy, O, Dusselier, L, Faucher-Kareche, S, Fendri, S, Fontaine, P, Galinat, S, Gentric, A, Gin, H, Glaise, F, Godeau, T, Gonzales, B, Got, I, Guerci, B, Guillausseau, P-J, Hadjadj, S, Hadjali, Y, Halbron, M, Halimi, S, Halter, C, Hanaire, H, Hardy, V, Hartemann-Heurtier, A, Haulot, J-P, Hequet, F, Issa-Sayegh, M, Jan, P, Jeandidier, N, Joseph-Henri, H, Julier, I, Kerlan, V, Kharitonnoff, T, Ladsous, M, Lahaxe, L, Lamaraud, M-P, Lassenne, E, Lecerf, J-M, Leroux, I, Lesven, S, Levy, M, Lopez, S, Makiza, F, Manckoundia, P, Pomeau, C Marquis, Mayaudon, H, Micheli, S, Mira, R, Monnier, F, Mosnier-Pudar, H, Neri, N, Normand, I, Paccalin, M, Pagu, C, Paris, D, Penfornis, A, Perie, J-L, Petit, J-M, Petit-Aubert, G, Pichot-Duclos, B, Pivois, L, Popelier, M, Poulingue, G, Priner, M, Quipourt, V, Rasamisoa, M, Richard, J-L, Rigalleau, V, Roudat, N, Sanz, C, Serot, J-M, Sifi, D, Sirvain, S, Slimani, A, Sonnet, E, Sosset, C, Soualah, A, Stroea, A, Tauveron, I, Timsit, J, Tschudnowsky, M, Vambergue, A, Verier-Mine, O, Virally, M, Le Floch, J.-P., Doucet, J., Bauduceau, B., and Verny, C.

Published
2014
Full Text
View/download PDF

26. Epidemiology of cardiovascular risk factors: Non-behavioural risk factors.

Author

Olié V, Gabet A, Grave C, Helft G, Fosse-Edorh S, Piffaretti C, Lailler G, Verdot C, Deschamps V, Vay-Demouy J, Vidal-Petiot E, Duly-Bouhanick B, Tuppin P, Ferrières J, Halimi JM, and Blacher J

Subjects
Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, France epidemiology, Hypertension epidemiology, Obesity epidemiology, Obesity diagnosis, Prevalence, Prognosis, Risk Assessment, Sex Factors, Cardiovascular Diseases epidemiology, Cardiovascular Diseases diagnosis, Cardiovascular Diseases prevention & control, Heart Disease Risk Factors
Abstract

Cardiovascular disease is the leading cause of death worldwide, and the second leading cause in France. Among the modifiable cardiovascular risk factors, metabolic diseases (hypertension, low-density lipoprotein hypercholesterolaemia, diabetes and obesity) play a major role, contributing to the development and progression of atherosclerosis. This review summarizes the latest epidemiological data available at a national level. In 2015, the prevalence among adults aged 18-74years was 17.2% for obesity, 7.4% for diabetes, 30.6% for hypertension, 23.3% for low-density lipoprotein hypercholesterolaemia and 1.5% for stage 3-5 chronic kidney disease. Awareness of these diseases among affected individuals was very poor, ranging from 23% for diabetes to 45% for hypertension. While the prevalence of obesity and hypertension remained stable between 2006 and 2015, the prevalence of diabetes increased significantly. Prevention of these risk factors, particularly through nutrition, as well as awareness and management of them, must be intensified to reduce the burden of cardiovascular diseases in France. Whereas the prevalence of metabolic factors remains higher in men, particular attention should also be paid to risk factors specific to women, such as gynaecological diseases (endometriosis, polycystic ovary syndrome) and pregnancy disorders (hypertensive disorders in pregnancy, gestational diabetes), which contribute significantly to cardiovascular risk., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)

Published
2024
Full Text
View/download PDF

27. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney.

Author

Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Jaén Águila F, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg F, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre I, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, der Niepen PV, Veglio F, Venzin R, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, and Vogt L

Subjects
Humans, Europe, Antihypertensive Agents therapeutic use, Male, Surveys and Questionnaires, Female, Middle Aged, Calcium Channel Blockers therapeutic use, Societies, Medical, Angiotensin Receptor Antagonists therapeutic use, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic drug therapy, Hypertension drug therapy
Abstract

Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management.

Published
2024
Full Text
View/download PDF

28. Catheter-based renal denervation in the treatment of arterial hypertension: An expert consensus statement on behalf of the French Society of Hypertension (SFHTA), French Society of Radiology (SFR), French Society of Interventional Cardiology (GACI), French Society of Cardiology (SFC), French Association of Private Cardiologists (CNCF), French Association of Hospital Cardiologists (CNCH), French Society of Thoracic and Cardiovascular Surgery (SFCTCV) and French Society of Vascular and Endovascular Surgery (SCVE).

Author

Pathak A, Boulestreau R, Sapoval M, Lantelme P, Duly-Bouhanick B, Benamer H, Bejan-Angoulvant T, Cremer A, Amar L, Delarche N, Ormezzano O, Sabouret P, Silhol F, Sosner P, Lopez-Sublet M, Cohen A, Courand PY, and Azizi M

Subjects
Humans, Antihypertensive Agents therapeutic use, Arterial Pressure, Catheter Ablation adverse effects, Catheter Ablation standards, Renal Artery innervation, Renal Artery diagnostic imaging, Risk Factors, Treatment Outcome, Consensus, Hypertension physiopathology, Hypertension diagnosis, Hypertension surgery, Hypertension therapy, Kidney innervation, Kidney blood supply, Sympathectomy adverse effects
Abstract

Several high-quality, randomized, sham-controlled trials have provided evidence supporting the efficacy and safety of radiofrequency, ultrasound and alcohol catheter-based renal denervation (RDN) for reducing blood pressure (BP). A French clinical consensus document has therefore been developed to propose guidance for the appropriate use of RDN in the management of hypertension along with a dedicated care pathway and management strategy. The French experts group concluded that RDN can serve as an adjunct therapy for patients with confirmed uncontrolled, resistant essential hypertension despite treatment with≥3 antihypertensive drugs, including a long-acting calcium channel blocker, a renin-angiotensin system blocker and a thiazide/thiazide-like diuretic at maximally tolerated doses. Patients should have (1) an estimated glomerular filtration rate of≥40mL/min/1.73m 2 ; (2) an eligible renal artery anatomy on pre-RDN scans and (3) exclusion of secondary forms of hypertension. Additional indications might be considered for patients with difficult-to-control hypertension. Any indication of RDN should be validated by multidisciplinary hypertension teams consisting of both hypertension specialists and endovascular interventionalists in European Society of Hypertension (ESH) Excellence Centres or ESH-BP clinics. Patients should be informed about the benefit/risk ratio of RDN. Expertise in renal artery interventions and training in RDN techniques are needed for endovascular interventionalists conducting RDN procedures while centres offering RDN should have the necessary resources to manage potential complications effectively. Lastly, all patients undergoing RDN should have their data collected in a nationwide French registry to facilitate monitoring and evaluation of RDN outcomes, contributing to ongoing research and quality improvement efforts., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)

Published
2024
Full Text
View/download PDF

29. Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

Author

Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Águila FJ, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg FP, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre IM, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, Van der Niepen P, Veglio F, Venzin RM, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, and Vogt L

Subjects
Humans, Surveys and Questionnaires, Male, Female, Pilot Projects, Referral and Consultation, Antihypertensive Agents therapeutic use, Middle Aged, Mass Screening methods, Europe, Aged, Glomerular Filtration Rate, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic physiopathology, Hypertension drug therapy, Hypertension complications
Abstract

Objective: Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear., Methods: A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management of CKD patients referred to ESH-Hypertension Excellence Centres (ESH-ECs) at first referral visit. The questionnaire contained 64 questions with which ESH-ECs representatives were asked to estimate preexisting CKD management quality., Results: Overall, 88 ESH-ECs from 27 countries participated (fully completed surveys: 66/88 [75.0%]). ESH-ECs reported that 28% (median, interquartile range: 15-50%) had preexisting CKD, with 10% of them (5-30%) previously referred to a nephrologist, while 30% (15-40%) had resistant hypertension. The reported rate of previous recent (<6 months) estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) testing were 80% (50-95%) and 30% (15-50%), respectively. The reported use of renin-angiotensin system blockers was 80% (70-90%). When a nephrologist was part of the ESH-EC teams the reported rates SGLT2 inhibitors (27.5% [20-40%] vs. 15% [10-25], P  = 0.003), GLP1-RA (10% [10-20%] vs. 5% [5-10%], P  = 0.003) and mineralocorticoid receptor antagonists (20% [10-30%] vs. 15% [10-20%], P  = 0.05) use were greater as compared to ESH-ECs without nephrologist participation. The rate of reported resistant hypertension, recent eGFR and UACR results and management of CKD patients prior to referral varied widely across countries., Conclusions: Our estimation indicates deficits regarding CKD screening, use of nephroprotective drugs and referral to nephrologists before referral to ESH-ECs but results varied widely across countries. This information can be used to build specific programs to improve care in hypertensives with CKD., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

30. [Management of arterial hypertension before 20weeks gestation in pregnant women].

Author

Seguro F, Duly Bouhanick B, Chamontin B, and Amar J

Subjects
Antihypertensive Agents therapeutic use, Decision Trees, Female, Humans, Hypertension therapy, Pregnancy, Pregnancy Complications, Cardiovascular therapy, Pregnancy Trimester, Second, Hypertension, Pregnancy-Induced therapy
Abstract

In the first 6 months of pregnancy, the primary goal of antihypertensive treatment is to prevent the complications of severe hypertension. Initiation of antihypertensive drug treatment is recommended in pregnant women with severe hypertension (blood pressure>160/110mmHg). Initiation of antihypertensive drug treatment should also be considered in pregnant women at high cardiovascular risk (diabetes, chronic kidney disease, personal history of cardiovascular disease) with moderate hypertension (blood pressure between 140-159/90-109mmHg). A systolic blood pressure goal<160 and a diastolic blood pressure goal between 85 and 100mmHg is recommended in pregnancy. Labetalol, nifedipine, nicardipine and alphamethyldopa should be considered preferential antihypertensive drugs in pregnancy. Salt restriction, physical exercise and weight loss have not demonstrated any effect in the prevention of preeclampsia and serious maternal complications of hypertension., (Copyright © 2016. Published by Elsevier Masson SAS.)

Published
2016
Full Text
View/download PDF

31. [Not Available].

Author

Gryn A, Duly-Bouhanick B, Bennet A, Almont T, Beauval J, Gas J, Roumiguié M, Thoulouzan M, Vezzosi D, Caron P, Amar J, Chamontin B, Gamé X, Malavaud B, Soulié M, Rischmann P, and Huyghe E

Published
2015
Full Text
View/download PDF

32. Retroperitoneoscopic adrenalectomy: comparison of retrograde and antegrade approach among a series of 279 cases.

Author

Huyghe E, Crenn G, Duly-Bouhanick B, Vezzosi D, Bennet A, Atallah F, Mazerolles M, Salloum A, Thoulouzan M, Delaunay B, Grunenwald S, Amar J, Plante P, Chamontin B, Caron P, and Soulié M

Subjects
Adrenalectomy adverse effects, Adrenergic Agents administration & dosage, Adult, Aged, Analgesics, Opioid, Anti-Arrhythmia Agents administration & dosage, Atropine administration & dosage, Blood Loss, Surgical, Blood Pressure, Cushing Syndrome surgery, Ephedrine administration & dosage, Female, Humans, Laparoscopy adverse effects, Male, Middle Aged, Morphine therapeutic use, Operative Time, Pain, Postoperative drug therapy, Pain, Postoperative etiology, Retroperitoneal Space, Adrenal Gland Neoplasms surgery, Adrenalectomy methods, Adrenocortical Adenoma surgery, Laparoscopy methods, Pheochromocytoma surgery
Abstract

Objective: To compare the results of retroperitoneal laparoscopic adrenalectomy using the antegrade and retrograde approach., Materials and Methods: We performed an analysis of a single-center series of 279 retroperitoneal laparoscopic adrenalectomies from 1996 to 2010. We compared 172 cases performed with an antegrade approach and 107 with a retrograde approach without dissection of the renal hilum and initial control of the adrenal vein in comparable populations., Results: The operative time was shorter in the group treated with the retrograde technique, 101±51 vs 140±40 minutes, respectively (Student's t test, P<.001). Blood loss was similar in both groups, 85±224 vs 80±126 mL, respectively (P=NS). Hemodynamic instability was defined as the maximal systolic blood pressure minus the minimal systolic blood pressure divided the maximal systolic blood pressure. It was lower in the group who underwent the retrograde technique (32.7 vs 37.6 mL; Student's t test, P=.005) with a lower perioperative consumption of ephedrine (2.2 vs 5.1 mg, P=.004) and atropine (0.09 vs 0.22 mg, P=.026). No difference was found between the 2 groups in the frequency of perioperative complications or postoperative mortality (1 death in each group of causes unrelated to the surgery)., Conclusion: Retroperitoneal laparoscopic adrenalectomy using a retrograde approach is a safe and reproducible technique. It makes it possible to perform adrenalectomy without dissection of the renal hilum, with a reduction in the operative time. The good hemodynamic stability observed with this technique makes it very attractive for the treatment of pheochromocytoma., (Copyright © 2013 Elsevier Inc. All rights reserved.)

Published
2013
Full Text
View/download PDF

33. [Prevention of cardiovascular diseases in type 2 diabetes with aspirin].

Author

Duly-Bouhanick B, Menard S, Hadjadj S, Soares-Barbosa S, Plun-Favreau J, and Guilloteau G

Subjects
Drug Prescriptions, Evidence-Based Medicine, Hemorrhage chemically induced, Humans, Patient Selection, Primary Prevention methods, Risk Factors, Aspirin therapeutic use, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 complications, Platelet Aggregation Inhibitors therapeutic use
Abstract

Unlabelled: THEORY AND REALITY: Diabetes mellitus is known to be associated with excess cardiovascular risk. Prescription of antiplatelet agents such as acetylsalicylic acid would thus appear to be warranted. That is the theory, but the reality is much different. A review of the literature provides evidence on the use of acetylsalicylic acid for primary and secondary preventive care, but conclusions are often extrapolated from studies conducted in the general population. EVIDENCE OF A BENEFICIAL EFFECT IN DIABETICS: The HOT study, conducted in hypertensive patients) demonstrated that acetylsalicylic acid at the dose of 75 mg a day, reduced the rate of major cardiovascular events by 15% (p = 0.03) and of myocardial infarction by 36% (p = 0.02) with no effect on stroke. In diabetic patients (n = 1500), the benefit was even more pronounced., Risks: The risk of bleeding must be balanced against the beneficial cardiovascular effect. Diabetic retinopathy is not aggravated by aspirin. The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results